Sjogren's Syndrome Clinical Trial
Official title:
Evaluation of Salivary Gland Dysfunction
This study will evaluate patients with complaints of dry mouth to determine the cause and
severity of their salivary gland dysfunction and their possible eligibility for other NIDCR
protocols. Salivary gland secretions have antibacterial, lubricatory, remineralizing,
digestive, buffering and cleansing properties. Impaired function of these glands can cause an
increase in tooth decay; a variety of oral hard and soft tissue changes, with painful,
burning, or ulcerated oral mucosal; problems chewing, swallowing, and speaking; and
diminished taste and smell.
Patients with dry mouth complaints suggestive of salivary gland dysfunction may be eligible
for this study. In addition, patients with recent onset of arthritis may enroll. Patients
with arthritis are at risk for developing a disorder called Sjogren's syndrome, in which the
glands that produce saliva may be damaged.
Participants will have a complete medical and dental history. Saliva samples will be
collected from the major salivary glands, which are located in the cheeks and under the jaw.
Several blood samples will also be drawn for tests. Some patients will have a biopsy of the
minor salivary glands, usually from the lower lip, to confirm or rule out the diagnosis of
Sjogren's syndrome and determine the extent of changes in the salivary glands. The ability to
taste and smell may also be evaluated, and patients may have an ultrasound examination of
their swallowing function.
This study will evaluate participants with complaints of dry mouth to determine the cause and
severity of their salivary gland dysfunction and their possible eligibility for other NIDCR
protocols. Salivary secretions have antibacterial, lubricating, remineralizing, digestive,
buffering and cleansing properties. Impaired function of these glands can cause an increase
in tooth decay; a variety of oral hard and soft tissue changes, with painful, burning or
ulcerated or oral mucosa; problems chewing, swallowing and speaking; and diminished taste and
smell.
Participants with dry mouth complaints suggestive of salivary gland dysfunction may be
eligible for this study.
Participants will have a complete medical and dental history. Saliva samples will be
collected from the major salivary glands, which are located in the cheeks and under the
tongue. Several blood samples will also be drawn for tests. Some participants will have a
biopsy of the minor salivary glands, usually from inside the lower lip, to confirm or rule
out the diagnosis of Sj(SqrRoot)(Delta)gren s syndrome and to determine the extent of changes
in the salivary glands. An eye examination including a standard eye examination and a dry eye
assessment is done. The ability to taste and smell may also be evaluated, and participants
may have an ultrasound examination of their swallowing function.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
| Completed |
NCT04968912 -
A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)
|
Phase 2 | |
| Completed |
NCT03203382 -
Corneal Nerve Structure in Sjogren's
|
||
| Completed |
NCT00809003 -
Assessment of Inflammatory and Functional Changes in the Ocular Surface Associated With Dry Eye Disease
|
N/A | |
| Completed |
NCT00023491 -
Potential of Transplanted Stem Cells to Mature Into Salivary Gland and Cheek Cells
|
N/A | |
| Completed |
NCT05005806 -
Fish Oil (Omega 3 ) in Sjogren's Syndrome
|
Phase 2/Phase 3 | |
| Enrolling by invitation |
NCT03436576 -
Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye
|
Phase 3 | |
| Terminated |
NCT04143841 -
Viveye Ocular Magnetic Neurostimulation System (OMNS) for the Management of Severe Dry Eye Disease
|
N/A | |
| Completed |
NCT03611283 -
Topical Management of Xerostomia With Dry Mouth Products
|
N/A | |
| Recruiting |
NCT06104124 -
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity
|
Phase 3 | |
| Recruiting |
NCT05115487 -
Evaluation of Hand Functions in Newly Diagnosed Primary Sjögren's Syndrome
|
||
| Recruiting |
NCT05383677 -
Anifrolumab Treatment for 24 Weeks in Patients With Primary Sjögren's Syndrome
|
Phase 2 | |
| Not yet recruiting |
NCT03938207 -
Dry Eye Syndrome, Healthy Control, Sjögren's Syndrome and Other Inflammation Disease in Taiwan Biobank
|
||
| Completed |
NCT04239521 -
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
|
||
| Completed |
NCT04546542 -
Hydroxychloroquine Blood Levels in Primary Sjögren Syndrome Patients
|
||
| Recruiting |
NCT05085431 -
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome
|
Early Phase 1 | |
| Completed |
NCT00565526 -
Evaluation of the Role of the Autonomic Nervous System in Sj(SqrRoot)(Delta)Gren s Syndrome
|
||
| Completed |
NCT01369589 -
An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness
|
Phase 1/Phase 2 | |
| Completed |
NCT00001953 -
The Functioning of Immune and Hormonal Systems in Patients With Sjogren's Syndrome and in Healthy Volunteers
|
N/A | |
| Completed |
NCT00001731 -
Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops
|
Phase 2 |